



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MARK A. ATKINSON SIHONG SONG SCOTT A. LOILER

Serial No.: Unknown

Filed: Concurrently Herewith

For: rAAV VECTOR-BASED

Commissioner for Patents

Alexandria, VA 22313-1450

P.O. Box 1450

Sir:

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT

OF MAMMALIAN DISEASES

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: 4300.014500

Customer No.: 23720

INFORMATION DISCLOSURE STATEMENT

EXPRESS MAILING LABEL 37 C.F.R. § 1.10


I hereby certify that this paper is being deposited with the U.S. Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" (Number EV 405388132 US) service on the date indicated and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 19, 2004

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed foreign patent documents and journal articles required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. Because the filing date of the present application is after June 30, 2003, copies of the listed U.S. patents are not included.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be





an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed within three months of the filing date of this patent application or prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Director is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4300.014500.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

WILLIAMS, MORGAN & AMERSON CUSTOMER NUMBER 23720

Date: October 19, 2004

Mark D. Moore, Ph.D.

Reg. No. 42,903

10333 Richmond, Suite 1100

Mark Illan

Houston, Texas 77042

(713) 934-4084

(713) 934-7011 (facsimile)

AGENT FOR APPLICANTS

DT01 ReCT/

1 9 OCT. 200

Form PTO-1449 (modified)

Atty. Docket No. 4300.014500

Serial No. 512008

List of Patents and Publications for Applicant's

Applicant

Mark A. Atkinson, Sihong Song and Scott A. Loiler

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

(Use several sheets if necessary)

Concurrently Herewith

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents
See Page 1

Other Art See Page1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,136,597	10/24/00	Hope et al.	435	325	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	В1	WO 99/55564	11/04/99	PCT	B60S	1/08	-

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation			
	C1	PCT Search Report from PCT/US03/12324			
	C2	Apparailly et al., "Tetracycline-Inducible Interleukin-10 Gene Transfer Mediated by an Adeno-Associated Virus: Application to Experimental Arthritis," Human Gene Therapy, 13:1179-88, 2002			
	C3	Flotte et al., "Efficient Ex Vivo Transduction of Pancreatic Islet Cells With Recombinant Adeno-Associated Virus Vectors," Diabetes, 50:515-20, 2001			
	C4	Goudy et al., "Adeno-associated virus vector mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice," PNAS, 98:13913-18, 2001			
	C5	Kapturczak et al., "Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery: Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes," Current Molecular Medicine, 1:245-58, 2001			
	C6	Mah et al., "Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy," Molecular Therapy, 6:106-12, 2002			
	C7	Song et al., "Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors," Proc. Natl. Acad. Sci. USA, 95:14384-88, 1998			
	C8	Song et al., "Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors," Gene Therapy, 8:1299-306, 2001			
	C9	Yang et al., "Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer." J. Immunology, 168:6479-85, 2002			

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.